FENNEC PHARMACEUTICALS INC. — Director's Dealing 2023

Apr 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FENNEC PHARMACEUTICALS INC. (FENC)
CIK: 0001211583
Period of Report: 2023-03-31

Reporting Person: Andrade Robert (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-31	Stock Option (right to buy)	$8.32	A	75000	Acquired	2033-03-31	Common Shares (75000)	Direct
2023-03-31	Restricted Share Unit (right to receive value of a share)	$0	A	37500	Acquired	2031-12-21	Common Shares (37500)	Direct

Footnotes

F1: On March 31, 2023, Robert Andrade was granted incentive stock options to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.

F2: 2. 1/3 of the shares subject to this option shall vest immediately and may be exercised as of March 31, 2024 (the "Vesting Commencement Date"). 1/24 of the shares subject to this option shall vest immediately and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2026 and thereafter, 100% of the total number of shares subject to this option shall be vested.

F3: 1. On March 31, 2023, Robert Andrade was awarded restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.

F4: 1/3 of the shares subject to this award shall be released from restriction as of March 31, 2024 (the "Vesting Commencement Date"). 1/24 of the award shall be released from restriction as of the last day of each month following the Vesting Commencement Date. As of March 31, 2026 and thereafter, 100% of the total number of shares subject to this award shall be released.